King Luther Capital Management Corp Has $274.95 Million Position in Danaher Corporation $DHR

King Luther Capital Management Corp cut its stake in Danaher Corporation (NYSE:DHR) by 11.1% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,386,811 shares of the conglomerate’s stock after selling 172,655 shares during the period. Danaher makes up about 1.1% of King Luther Capital Management Corp’s portfolio, making the stock its 19th biggest holding. King Luther Capital Management Corp owned approximately 0.20% of Danaher worth $274,949,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently modified their holdings of the stock. Norges Bank bought a new position in Danaher in the 2nd quarter valued at about $1,979,503,000. Viking Global Investors LP boosted its position in shares of Danaher by 543.9% during the 2nd quarter. Viking Global Investors LP now owns 2,907,515 shares of the conglomerate’s stock worth $574,351,000 after acquiring an additional 2,455,994 shares in the last quarter. Generation Investment Management LLP increased its stake in Danaher by 56.2% in the second quarter. Generation Investment Management LLP now owns 4,965,646 shares of the conglomerate’s stock valued at $980,914,000 after acquiring an additional 1,787,522 shares during the last quarter. Primecap Management Co. CA raised its position in Danaher by 924.2% during the second quarter. Primecap Management Co. CA now owns 1,239,320 shares of the conglomerate’s stock valued at $244,815,000 after purchasing an additional 1,118,318 shares in the last quarter. Finally, Vanguard Group Inc. lifted its stake in Danaher by 1.3% during the second quarter. Vanguard Group Inc. now owns 60,769,587 shares of the conglomerate’s stock worth $12,004,424,000 after purchasing an additional 788,499 shares during the last quarter. 79.05% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting Danaher

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Danaher agreed to buy Masimo for roughly $9.9 billion (cash, $180 per share), adding pulse oximetry and patient-monitoring tech to its Diagnostics segment — management says Masimo will operate as a stand‑alone business, preserving its commercial footprint. Danaher to buy Masimo for $9.9 billion
• Positive Sentiment: Deal size and strategic rationale frame this as one of 2026’s largest med‑tech buyouts — investors view it as a clear move to bulk up Diagnostics and widen cross‑sell and lifecycle offerings. Danaher’s $9.9B Masimo Deal Marks One of 2026’s Largest Medtech Buyouts
• Positive Sentiment: Market reaction: Masimo shares surged on the announcement, and Danaher shares moved on acquisition buzz as traders priced in strategic upside and potential revenue/scale benefits. Shares of Masimo, Danaher Moving on Acquisition Buzz
• Neutral Sentiment: Coverage notes Danaher’s solid underlying financials and relatively conservative growth projections — this suggests the deal is being integrated into a cautious growth outlook rather than signaling aggressive upside guidance. Danaher’s Masimo acquisition: Solid financials, conservative growth projections
• Neutral Sentiment: Danaher’s broader business shows stabilizing areas (notably bioprocessing), which provides a steadier earnings base to absorb bolt‑on M&A. Danaher Corp. (DHR) Signaled Signs of a Stable Bioprocessing Segment
• Negative Sentiment: The $9.9B all‑cash price and premium paid could pressure near‑term free cash flow and capital allocation; investors will watch integration costs, any leverage changes, and whether the deal proves accretive. Danaher Strikes $10 Billion Deal for Masimo

Danaher Price Performance

Shares of NYSE:DHR opened at $208.51 on Thursday. The company has a debt-to-equity ratio of 0.35, a quick ratio of 1.51 and a current ratio of 1.87. Danaher Corporation has a 52 week low of $171.00 and a 52 week high of $242.80. The firm has a market cap of $147.28 billion, a PE ratio of 41.37, a price-to-earnings-growth ratio of 2.79 and a beta of 0.91. The firm’s fifty day moving average is $227.62 and its 200-day moving average is $215.72.

Danaher (NYSE:DHR) last announced its earnings results on Tuesday, January 27th. The conglomerate reported $2.23 EPS for the quarter, topping the consensus estimate of $2.14 by $0.09. The firm had revenue of $6.84 billion for the quarter, compared to the consensus estimate of $6.79 billion. Danaher had a return on equity of 10.81% and a net margin of 14.71%.The business’s quarterly revenue was up 4.6% compared to the same quarter last year. During the same period in the previous year, the business earned $2.14 EPS. Sell-side analysts predict that Danaher Corporation will post 7.63 earnings per share for the current year.

Danaher Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, January 30th. Stockholders of record on Friday, December 26th were given a dividend of $0.32 per share. The ex-dividend date was Friday, December 26th. This represents a $1.28 annualized dividend and a dividend yield of 0.6%. Danaher’s dividend payout ratio is 25.40%.

Analysts Set New Price Targets

DHR has been the subject of several recent analyst reports. Wall Street Zen upgraded Danaher from a “hold” rating to a “buy” rating in a research report on Saturday, November 22nd. Argus set a $265.00 target price on shares of Danaher in a report on Wednesday, January 14th. Barclays lifted their price target on shares of Danaher from $225.00 to $250.00 and gave the company an “overweight” rating in a report on Wednesday, October 22nd. Evercore reissued an “outperform” rating and issued a $254.00 price objective on shares of Danaher in a research note on Wednesday, January 28th. Finally, Morgan Stanley initiated coverage on shares of Danaher in a research report on Monday, December 1st. They issued an “overweight” rating and a $270.00 target price on the stock. Twenty equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Danaher has a consensus rating of “Moderate Buy” and an average target price of $253.86.

Danaher Company Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.